Events and Presentations

Date

Title

Supporting Materials

Piper Sandler Virtual Healthcare Conference Presentation 1.9 MB

Supporting Materials

Stifel 2020 Virtual Healthcare Conference Presentation 1.9 MB

Supporting Materials

Morgan Stanley Global Healthcare Conference Presentation 1.8 MB

Supporting Materials

Investor Presentation 2.5 MB

Supporting Materials

ISTH – Marzeptacog alfa (activated) population pharmacokinetics (PK): Simulations for dose selection in Phase 3 trials 2.1 MB

ISTH – Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of ascending doses of subcutaneous marzeptacog alfa (activated) in adult subjects with hemophilia 1 MB

Supporting Materials

WFH - Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy 2 MB

Supporting Materials

Phase 2b Trial to Evaluate the Safety and Factor IX Levels of a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog alfa in Hemophilia B 2.1 MB

Supporting Materials

Phase 2b Trial to Evaluate the Safety & Factor IX Levels Resulting from a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog Alfa in Haemophilia B 528.7 KB

Supporting Materials

Phase 2b Trial to Evaluate the Safety & Factor IX Levels Resulting from a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog Alfa in Haemophilia B 528.7 KB

Supporting Materials

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports On-Demand Treatment in Hemophilia A Mice 1.8 MB

Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of ascending doses of subcutaneous marzeptacog alfa (activated) in adult subjects with hemophilia 519.2 KB

Hemophilia B Gene Therapy in Mice Using a Novel Chimeric AAV Capsid Combined With the Potency Enhanced CB 2679d-GT FIX Variant 1.4 MB

Supporting Materials

Catalyst Biosciences at the ASBMB Conference Presentation 12.2 MB

Supporting Materials

KOL event for analysts and investors on MarzAA, next-generation Factor VIIa Marzeptacog alfa (activated) in individuals with bleeding disorders Presentation 15.3 MB

Supporting Materials

Phase 2/3 Trial of Subcutaneous Engineered FVIIa Marzeptacog Alfa (Activated) in Hemophilia A or B with Inhibitors: Efficacy, Safety and Pharmacokinetics 394.8 KB

Quality of Life of Hemophilia Patients with Inhibitors – Opportunities for Improvement 709 KB

Phase 2 Trial of Subcutaneous Engineered FIX Dalcinonacog alfa: Pharmacokinetics and Safety 422.7 KB

A Comprehensive In Silico And In Vitro Immunogenicity Risk Assessment of Dalcinonacog Alfa Shows No Increased Risk Compared With Wild-type FIX 1.8 MB

Supporting Materials

CB 2782-PEG: a Complement Factor C3-Inactivating Protease and Potential Long- Acting Treatment for Dry AMD 1.6 MB

Home
Contact